First-in-class Phase 1 data for two investigational bispecifics in advanced ovarian cancer and advanced MET-altered non-small cell lung cancer (NSCLC) to be presented
Additional presentations include new data for investigational Libtayo monotherapy and combination therapies in advanced melanoma, NSCLC and cervical cancer, as well as neoadjuvant cutaneous squamous cell carcinoma
Regeneron will host an investor webcast on Monday, September 12 at 8:00 AM ET to provide updates across its oncology portfolio
TARRYTOWN, N.Y., Sept. 4, 2022 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that new and updated data across its oncology pipeline will be presented at the European Society for Medical Oncology (ESMO) Congress 2022 from September 9 to 13 in Paris. Presentations will include first-in-class efficacy and safety data from Phase 1/2 trials of…
